The Seoul-based company also recently raised $1.9 million in series B funding and is targeting between $7 million and $8 million to close the round.
The test has been validated for use with the same full set of female urogenital specimens that are used with Cobas NT/NG testing, as well as for use with male urine.
Quest's CEO gave an overview of the firm's business and the lab space in general, while GenMark launched a new system this week aimed at smaller labs.
The Singapore-based firm has established a US subsidiary and named distributors to sell its products across Europe, the Middle East, and Asia.
The sequencing-based, laboratory-developed test, called SmartJane, contains the first commercially available vaginal microbiome assay.
The company recently released the MGISEQ-2000, MGISEQ-200, and MGIFLP sequencing platforms, as well as the MGIUS-R3 robotic ultrasound system.
Pacific Toxicology Laboratories has expanded its menu to include fentanyl and its analogues as deaths surge from synthetic opioid overdoses.
The firm said that entry into the market is a logical progression based on its existing position and strength in hematology, an adjacent segment.
The firm said the point-of-care test would help clinicians rapidly decide whether an upper respiratory infection is viral, bacterial, or clinically insignificant.
A recent study has shown that the biomarker used by the test, GDF-15, is a strong predictor of bleeding risk in patients with atrial fibrillation.